The EU Commission presents its preliminary results concerning the pharmaceutical sector inquiry raising competition concerns

"Preliminary results of Commission pharmaceutical sector inquiry raise competition concerns"* On 28 November 2008, the Commission presented the preliminary findings of its sector inquiry into pharmaceuticals. The report [1] shows that originator companies engage in practices that can contribute to delayed generic entry. The report also states that originator companies use patent strategies aimed at blocking or delaying the development of novel medicines by competitors. This article explains the rationale for launching the sector inquiry and presents the preliminary findings. I. Context The pharmaceutical sector is essential for the health of Europe’s citizens, who need access to innovative, safe and affordable medicines. A lot of money is at stake: each European consumer paid almost

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Fabio Domanico, Elena Kamilarova, Alexander Riedl, The EU Commission presents its preliminary results concerning the pharmaceutical sector inquiry raising competition concerns, 28 November 2008, e-Competitions Bulletin November 2008, Art. N° 35137

Visites 349

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues